Bronchiolitis obliterans after lung transplantation is a major cause of postoperative mortality in which T cell-mediated immunity is known to play an important role. However, the exact contribution of natural killer (NK) cells, which have functions similar to CD8 + T cells, has not been defined. Here, we assessed the role of NK cells in murine bronchiolitis obliterans through heterotopic tracheal transplantations and found a greater percentage of NK cells in allografts than in isografts. Depletion of NK cells using an anti-NK1.1 antibody attenuated bronchiolitis obliterans in transplant recipients compared with controls. In terms of NK cell effector functions, an improvement in bronchiolitis obliterans was observed in perforin-KO recipient mice compared to wild type (WT). Furthermore, we found upregulation of NKG2D-ligand in allografts and demonstrated the significance of this using grafts expressing Rae-1, a murine NKG2D-ligand, which induced severe bronchiolitis obliterans in WT and Rag-1 KO recipients. This effect was ameliorated by injection of anti-NKG2D blocking antibody. Together, these results suggest that cytotoxicity resulting from activation of NK cells through NKG2D leads to the development of murine bronchiolitis obliterans.
Bronchiolitis obliterans after lung transplantation is a major cause of postoperative mortality in which T cell-mediated immunity is known to play an important role. However, the exact contribution of natural killer (NK) cells, which have functions similar to CD8 + T cells, has not been defined. Here, we assessed the role of NK cells in murine bronchiolitis obliterans through heterotopic tracheal transplantations and found a greater percentage of NK cells in allografts than in isografts. Depletion of NK cells using an anti-NK1.1 antibody attenuated bronchiolitis obliterans in transplant recipients compared with controls. In terms of NK cell effector functions, an improvement in bronchiolitis obliterans was observed in perforin-KO recipient mice compared to wild type (WT). Furthermore, we found upregulation of NKG2D-ligand in allografts and demonstrated the significance of this using grafts expressing Rae-1, a murine NKG2D-ligand, which induced severe bronchiolitis obliterans in WT and Rag-1 KO recipients. This effect was ameliorated by injection of anti-NKG2D blocking antibody. Together, these results suggest that cytotoxicity resulting from activation of NK cells through NKG2D leads to the development of murine bronchiolitis obliterans.
Introduction
Although lung transplantation (LTx) is regarded as an effective strategy for patients with end-stage lung disorders, graft rejection is a more common complication for this procedure than for all other solid-organ transplantations (1, 2) . The need for LTx has been steadily increasing, with almost 4000 cases being performed in 2013 alone. However, the 5-year survival rate after LTx is only about 50%, and the most common cause of death is bronchiolitis obliterans (BO), which is recognized as chronic rejection (3) .
About half of patients who undergo LTx develop BO within 5 years (3) , and this disease is characterized by a persistent peribronchial inflammation of the graft caused by immunological injuries, which leads to airway fibrosis and occlusion (4) . Since BO is a progressive disease and improvement of symptoms is rarely observed, the inevitable result of BO is respiratory failure.
It has been reported that BO is mainly induced by T cellmediated immunological responses (5) (6) (7) (8) . Thus, CD4 + T cells activated by recipient antigen-presenting cells produce cytokines, such as interferon-ɤ (IFN-ɤ) and tumornecrosis factor a (TNF-a), which induce the generation and expansion of alloreactive CD8 + T cells in the donor lung, resulting in BO development (9) . In addition, donorspecific antibodies also have been revealed to play a role in the development of BO after LTx (10) (11) (12) . Despite the large amount of research, BO is still refractory and a major threat to survival post-lung transplantation (4) . Natural killer (NK) cells exert perforin-mediated cytotoxicity and produce cytokines such as IFN-ɤ and TNF-a. To eliminate target cells, NK cells recognize ligands through activating or inhibitory receptors (13) . NKG2D is an extensively characterized NK activating receptor (14) whose ligands include retinoic acid early inducible-1 (Rae-1), H60, and murine UL-16 binding protein-like transcript 1 in mice, as well as UL-16 binding protein, and MHC class I chain-related molecule A(MICA) and B(MICB) in humans (15) . Moreover, NKG2D is expressed on essentially all NK cells, and plays a crucial role in NK-mediated effector functions (16) .
CD8
+ T cells, which exert perforin-mediated cytotoxicity and produce IFN-ɤ, play an important role in the development of BO and contribute to lung allograft rejection (5, 6) . Since NK cells also have effector functions including perforin-mediated cytotoxicity and the ability to produce IFN-ɤ, it is possible that NK cells play a crucial role in the development of BO. However, the role of NK cells and the molecular mechanisms that activate them following LTx have not been defined.
To this end, we asked whether NKG2D on NK cells contributes to the development of BO, and assessed the effector functions of NK cells in the development of BO.
Methods

Ethics statement
Mice were maintained under specific pathogen-free conditions, and all procedures were performed according to the protocols approved by the Institutional Committee for Use and Care of Laboratory Animals of Tohoku University, granted by the Tohoku University Ethics Review Board (No.2012AcA-069), and the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication 85-23, revised 1996). All surgeries were performed with the mice under anesthesia. For collection of tissue samples, mice were sacrificed by cervical dislocation. All efforts were made to minimize suffering.
Mice
C57BL/6, BALB/c, and CB17 scid/scid female mice (6-9 weeks old) were obtained from CLEA Japan (Tokyo). Perforin KO (PRF-KO), IFN-ɤ KO (IFN-ɤ-KO), and Rag-1 KO mice were obtained from Jackson Laboratory (Bar Harbor, ME). Rae-1 transgenic mice were generated as previously described (17) .
Antibodies and cell lines
Mouse blocking monoclonal antibody (mAb) to NKG2D (clone CX5), mouse depleting mAb to NK1.1 (clone PK136), and mouse depleting mAb to CD8 (clone 53-6.7) were purified as previously described (17) . Polyclonal rabbit anti-asialo GM1 Ab was purchased from Wako (Osaka, Japan) and control rat IgG (control-Ig) was purchased from Sigma-Aldlich (St Louis, MO). Ba/F3 cells were stably transfected with mouse IL-3 cDNA plasmid to provide for autocrine growth (grown in RPMI 1640, 10% FCS, penicillin/streptomycin). Rae-1 transfectants (Ba/F3-Rae1) were established by retroviral transduction (18) .
Heterotopic tracheal transplantation
The well-established heterotopic tracheal transplant model was used (19) . The luminal obliteration of the trachea graft in this model is regarded as BO (20) . The tracheal segment of donor C57BL/6 (isograft) or BALB/c (allograft) mice was transplanted subcutaneously into recipient C57BL/6 mice. Grafts were evaluated 21 days after transplantation (n = 4-7 for each). Mice were injected intraperitoneally once a week with 1 mg of mAb to NKG2D, NK1.1, CD8, or a control-Ig, and 50 lg of anti-asialo GM1 (Wako) was injected twice a week after transplantation, as previously described (21, 22) .
Histological analysis
At 21 days after heterotopic tracheal transplantation, trachea grafts were formalin fixed and paraffin embedded. Sections obtained from the center of the grafts were stained by hematoxylin-eosin or elastic-Masson's trichrome. The luminal obliterations of grafts were mechanically peeled off using Histquest software (TissueGnostics GmbH, Vienna, Austria) (23).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue of the tracheal graft sections were deparaffinized with xylene and rehydrated in a series of solutions with decreasing concentrations of ethanol. Heat-induced antigen retrieval was carried out in an autoclave (120°C) for 5 min in 0.01 M sodium citrate buffer (pH 6.0). Slides were incubated with the anti-Rae-1 polyclonal antibody (AF1136; R&D Systems, Minneapolis, MN) at a dilution of 1:200 overnight at 4°C, and then endogenous peroxidase was inactivated by 0.3% hydrogen peroxide for 20 min at room temperature. After incubation for 45 min with secondary antibody, Histofine MAX-PO (G) (414351, Nichirei Bioscience Inc., Tokyo, Japan), color development and contrast were achieved using DAB and hematoxylin.
Quantitative PCR
Total RNA was reverse transcribed into cDNA using SuperScript III with Oligo (dT)12-18 (Invitrogen, Carlsbad, CA). Quantitative polymerase chain reaction (qPCR) was performed in a DNA chromo 4 (Bio-Rad Laboratories, Hercules, CA). PCR primers listed in Table 1 were used for quantification of the amplified DNA. Data were analyzed using Opticon Monitor version 3 software (Bio-Rad Laboratories), according to manufacturer's instructions.
Lymphocyte preparation
Lymphocytes were taken from murine spleens or transplanted tracheas as previously described (24) . In brief, tissues were minced and filtered using 100-lm mesh. Erythrocytes were lysed osmotically. After two washes, cells were again filtered using 100-lm mesh and were then 
Primary lung cell preparation
Primary lung cells were taken from murine lungs as previously described (25) . In brief, mice were anesthetized using isoflurane and perfused with phosphate-buffered saline (PBS) by heart puncture for blood removal. After lungs were isolated and filled with dispase II (Sigma-Aldrich, St Louis, MO), they were incubated for 45 min at 37°C with PBS containing 0.1% DNase (Sigma-Aldrich) and 0.1% collagenase/dispase (Roche, Basel, Switzerland). Lungs were minced into small pieces followed by further incubation for 15 min at 37°C. After filtration using 100-lm mesh, erythrocytes were lysed osmotically. After two washes, cells were again filtered using 100-lm mesh and were resuspended in RPMI-1640 medium containing 10% FCS.
Flow cytometric analysis
Lymphocytes were isolated from grafts at 21 days postheterotopic tracheal transplantation. Lymphocytes were stained with PE-labeled anti-CD3 (BioLegend, San Diego, CA) and APC-labeled anti-NK1.1 (BioLegend) or control antibodies to identify NK cells (CD3 
LDH release assay
Single cells from C57BL/6 or BALB/c lungs were incubated for 3 days, and adherent lung cells were used as targets. Effector cells were freshly isolated C57BL/6 lymphocytes depleted of CD8 + T cells by intraperitoneal injection of 300 lg anti-CD8 antibody 3 days before isolation. Effector cells and 1.0 9 10 5 target cells were co-cultured in 96-well U-bottomed plates for 4 h at effector/target (E/T) ratios of 100:1, 50:1, or 25:1. Supernatants were collected, and the lactate dehydrogenase (LDH) release was evaluated using the Cytotox 96 â Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI) according to manufacturer's instructions. The percentage of specific lysis was calculated according to the following formula: % specific lysis = (experimental-target spontaneous-effector spontaneous) LDH release 9 100/(target maximal-target spontaneous) LDH release.
51
Cr release assay 51 Cr release assay was performed as described (24) . In brief, target cells were labeled with 50 lCi of Na 2 ( 51 Cr)O 4 for 60 min at 37°C in RPMI-1640 medium containing 10% FCS, and were washed three times with medium prior to their use.
Cr-labeled target cells (1.0 9 10 4 ) and effector cells were mixed in 96-well U-bottomed plates at the indicated E/T ratios. After a 4-h co-culture, the supernatants were collected, and radioactivity was measured using a gamma counter.
The percentage of specific lysis was calculated according to the following formula: % specific lysis = (experimental-spontaneous) 51 Cr release 9 100/(maximal-spontaneous) 51 Cr release.
Statistical analysis
Statistical analysis was performed using the unpaired two-tailed Student's t-test: *p < 0.05; **p < 0.01. All data are represented as the mean AE standard deviation.
Results
Upregulation of perforin and IFN-ɤ in allografts in the murine BO model To investigate the immunoreactions taking place during BO, we compared NK cell effector functions following transplantation of isografts and allografts. For these studies, heterotopic tracheal transplantations were conducted in mice, which is a well-known model for BO. Consistent with previous reports (26, 27) , preservation of airway architecture and luminal patency were observed in isografts, but not in allografts ( Figure 1A ). Moreover, there was a significant difference in the development of BO between isografts and allografts, with 8.4% luminal obliteration being observed in isografts, and 76.0% luminal , and TNF-a (E) mRNAs in the grafts were evaluated by qPCR. The expression of each gene was compared with that in native BALB/ c or C57BL/6 tracheas. *P < 0.05, **P < 0.01. BO, bronchiolitis obliterans; EM, elastic-Masson's trichrome; HE, hematoxylineosin; IFN, interferon-ɤ; NS, not significant; qPCR, quantitative polymerase chain reaction; TNF-a, tumor necrosis factor-a.
obliteration in allografts 21 days after transplantation (Figure 1B) . To examine whether effector functions related to NK cells are involved in the development of BO, we measured perforin, IFN-ɤ, and TNF-a in the graft by qPCR and found significant differences in the expression of perforin and IFN-ɤ between isografts and allografts. The expression of perforin was upregulated 8.0-fold in allografts compared to native BALB/c tracheal grafts, whereas perforin expression in isografts was just 0.77-fold more than in the control ( Figure 1C) . Similarly, the expression of IFN-ɤ in allografts was 44.9 times greater than that of native BALB/c tracheal grafts, compared to a 1.9-fold increase of control in isografts ( Figure 1D ). However, no significant difference was found in the expression of TNF-a between isografts and allografts ( Figure 1E ). Thus, the effector functions mediated by perforin and IFN-ɤ are upregulated during the development of BO.
Cytotoxicity plays a crucial role in the development of BO To evaluate the roles of perforin and IFN-ɤ in the development of BO, we investigated luminal obliteration after heterotopic tracheal allo-transplantations using PRF-KO or IFN-ɤ-KO mice as recipient mice. Preservation of tracheal surface epithelium and luminal patency were only observed in allografts transplanted into PRF-KO mice, and not in the allografts transplanted into IFN-ɤ-KO or WT mice (Figure 2A ). There was a significant difference in the development of BO between allografts transplanted into PRF-KO and those into WT, with 38.1% luminal obliteration being observed in allografts transplanted into PRF-KO and 76.0% luminal obliteration in WT 21 days after transplantation. On the other hand, no difference was observed in the amount of luminal obliteration between the allografts transplanted in IFN-ɤ-KO and WT mice ( Figure 2B ). These results suggest that cytotoxicity, but not IFN-ɤ production, is the effector function that plays a crucial role in the development of BO.
Dramatic upregulation of NK cells in allografts of murine BO
The results above prompted us to examine which populations of lymphocytes are involved in the development of BO. Thus, we evaluated the number of lymphocytes in isografts and allografts at 21 days after heterotopic tracheal transplantation by hemocytometer. The number of infiltrating lymphocytes in allografts was markedly higher (4.5 9 10 3 cells) than that in isografts (0.5 9 10 3 cells) ( Figure 3A) . Furthermore, the population of NK cells (NK1.1 + & CD3 À ) was significantly increased in allografts (12.7% in allografts and 2.6% in isografts) ( Figures 3B-D) . Therefore, there was a substantial increase in NK cells in allografts (571 NK cells in an allograft vs. 13 NK cells in an isograft) ( Figure 3E ). These results suggest NK cells may contribute to the development of BO.
NK cells contribute to the development of BO through their cytotoxicity To investigate the contribution of NK cells in the mouse BO model, NK1.1 + cells, which contain NK cells and NKT cells, were depleted in recipient mice using anti-NK1.1 mAb, NK cells were depleted using antiasialo GM1, and CD8 + T cells were depleted using anti-CD8 mAb. The occurrence of luminal obliteration as a result of heterotopic tracheal allo-transplantation into these mice was then examined. Preservation of tracheal surface epithelium was observed in the allografts transplanted into mice treated with anti-NK1.1 mAb, anti-asialo GM1, or anti-CD8 mAb, but not in the mice treated with control-Ig ( Figure 4A ). There was significant improvement in the luminal obliteration of allografts in mice treated with anti-NK1.1 mAb (55.0% luminal obliteration), antiasialo GM1 (32.2% luminal obliteration), and anti-CD8 mAb (30.1% luminal obliteration) compared to allografts in mice treated with control-Ig (87.0% luminal obliteration). In contrast, there was no significant difference in the amount of luminal obliteration between the allografts in mice treated with anti-NK1.1 mAb, anti-asialo GM1, or anti-CD8 mAb ( Figure 4B ). Next, to examine whether injection of anti-NK1.1 mAb in recipient mice contributed to the reduction of cytotoxicity seen in the allografts, the expression of perforin was measured by qPCR. In allografts treated with anti-NK1.1 mAb, perforin was expressed 0.53-fold more than in allografts in mice treated with control-Ig. This result suggests that the intraperitoneal injection of anti-NK1.1 mAb in recipient mice contributed to the reduction in cytotoxicity in the allografts ( Figure 4C ). Furthermore, to determine whether the cytotoxicity of NK cells contributes to the development of BO, we utilized an LDH release assay. C57BL/6 or BALB/c lung cells were utilized as target cells and CD8 + T cell-depleted C57BL/6 lymphocytes were used at the indicated E/T ratios as effector cells. Cytotoxicity of 16.4% was observed in BALB/c lung cells and 4.0% cytotoxicity in C57BL/6 lung cells at an E/T ratio of 100:1. The NK cytotoxicity had a marked impact on allogeneic targets compared to that seen with syngeneic targets (Figure 4D) . These results suggest that NK cells contribute to the development of BO through their cytotoxicity.
Upregulation of Rae-1, an NKG2D ligand, in allografts To examine whether NKG2D on NK cells contributes to the development of BO, we measured the expression of several NK cell activating ligands, such as Rae-1, CD155, and intercellular adhesion molecule-1 (ICAM-1), in isografts and allografts by qPCR. Rae-1 mRNA was expressed 148.2-fold more in allografts than in native grafts. In contrast, there was only a 6.7-fold increase in Rae-1 mRNA expression in isografts compared to native grafts. Thus, there was a striking upregulation of Rae1, an NKG2D ligand, in allografts compared to the relatively minor upregulation of this mRNA in isografts. On the other hand, there was no significant difference in the expression of CD155 or ICAM-1 between native grafts, allografts, or isografts. As shown in Figure 5B , ). E/T ratios were 100:1, 50:1, or 25:1. The supernatants were collected, and LDH release in the supernatants was evaluated using a colorimetric reaction. The percentage of specific lysis was calculated according to the following formula: % specific lysis = (experimental-target spontaneous-effector spontaneous) LDH release 9 100/(target maximal-target spontaneous) LDH release. The data are presented as means plus SDs of triplicates. *P < 0.05, **P < 0.01. BO, bronchiolitis obliterans; EM, elastic-Masson's trichrome; E/T ratios, effector/target ratios; HE, hematoxylin-eosin; LDH, lactate dehydrogenase; mAb, monoclonal antibody; NK, natural killer; NS, not significant; qPCR, quantitative polymerase chain reaction; SDs, standard deviations immunohistochemistry confirmed the striking level of Rae-1 protein expression in allografts compared with isografts. Therefore, these findings suggest that the activation of NK cells through Rae-1, an NKG2D ligand, contributes to the development of BO.
Activation of NK cells via NKG2D contributes to the development of BO
To determine whether the expression of Rae-1 contributes to the development of BO, we investigated luminal obliteration following heterotopic tracheal isotransplantations and allo-transplantations of tracheal grafts from Rae-1 transgenic mice. In Rae-1 transgenic isografts, there was a marked increase in infiltrating lymphocytes compared to that seen in WT isografts, and the tracheal surface epithelium was completely disappeared. Moreover, there were also more infiltrating lymphocytes in Rae-1 transgenic allografts than in WT allografts, and the airway architecture and luminal patency were almost completely destroyed ( Figure 6A ). Luminal obliteration in Rae-1 transgenic isografts was 24.7%, which was significantly increased over that of WT isografts at 8.4% (Figure 6B) . Furthermore, the luminal obliteration of Rae-1 transgenic allografts was 97.4%, which was significantly more than that of WT allografts (76.0%) ( Figure 6C) . To investigate the effect of blocking NKG2D on BO, we measured luminal obliteration following heterotopic tracheal allo-transplantations into mice treated by intraperitoneal injection with anti-NKG2D blocking mAb or control-Ig. As expected, airway architecture and luminal patency were preserved in the allografts treated with anti-NKG2D blocking mAb compared with control-Ig (Figure 6D) . Moreover, there was a significant improvement in the luminal obliteration of allografts in mice treated with anti-NKG2D blocking mAb (45.6% luminal obliteration) compared to allografts in mice treated with controlIg (87.0% luminal obliteration) ( Figure 6E ). To address whether NK cells activated through NKG2D develop BO by themselves, we measured luminal obliteration following heterotopic tracheal allo-transplantations of tracheal grafts from Rae-1 transgenic or WT mice into Rag-1 KO mice. As expected, there were more infiltrating lymphocytes in Rae-1 transgenic allografts than in WT allografts, and the airway architecture and luminal patency were destroyed in Rae-1 transgenic allografts ( Figure 6F ). Luminal obliteration in Rae-1 transgenic allografts was 32.7%, which was significantly increased over that of WT allografts (12.6%) ( Figure 6G ). Moreover, to evaluate whether the expression of NKG2D ligand would cause NK cell cytotoxicity, we performed a 51 Cr release assay using either Ba/F3-Rae1 or Ba/F3 as target cells and freshly isolated C57BL/6 lymphocytes (depleted of CD8 + T cells by intraperitoneal injection of 300 lg anti-CD8 antibody 3 days before isolation) as effector cells. At an E/T ratio of 50:1, 42.4% of Ba/F3-Rae1 target cells were killed compared to 5.3% of Ba/F3 target cells ( Figure 6F ). Overall, these results suggest that the activation of NK cells via NKG2D results in the development of BO, and that NKG2D stimulation strongly affects the cytotoxicity of NK cells. 
Discussion
In this study, we provide evidence in a murine heterotopic tracheal transplant model that NK cells play an important role in the development of BO through their cytotoxicity. In addition, the interaction between NKG2D and its ligands strongly affected the cytotoxicity of NK cells.
BO after LTx was first described in 1984 in heart-lung transplant recipients at Stanford University (28) . Despite the amount of research regarding the role of the immune system in BO, the role NK cells play in this process has remained unclear. Recently, several researchers have suggested that NK cells play important roles in rejection after bone marrow (17) and heart transplantations (29) . In addition, it has been revealed that there is an increase in NK cell numbers and activation in the lungs of patients with BO following LTx (30) . Indeed, we found that NK cells play an important role in the development of murine BO. Not only did the percentage of NK cells increase in allografts compared with isografts ( Figures 3A, B) , but also there was a decrease in luminal obliteration in allografts following depletion of NK cells from recipients ( Figures 4A, B) . Although after lung or skin transplantations NK cells have been shown to contribute to allograft acceptance by depleting donor-derived dendritic cells (31, 32) , this beneficial effect of NK cells is indicated to be transient and compromised after infiltration of mature recipient dendritic cells (31) . In contrast, in this study NK cells were found to contribute to the development of BO after LTx, which is known as chronic rejection. It is possible that the role of NK cells changes over the course of time after LTx, presenting beneficial effects during the acute stage and harmful effects in the chronic stage.
Next, we addressed the effector functions of NK cells and found that perforin-mediated cytotoxicity plays a key role in the development of BO (Figures 2A, B) . Furthermore, in vitro assessment of the cytotoxicity of NK cells showed a strong effect on allogeneic targets compared with syngeneic targets (Figures 4) . Indeed, both CD8 + T cell depletion and NK cell in recipient mice resulted in a reduction in the severity of BO (Figures 4A, B) . Previously, the cytotoxicity of NK cells has not been investigated in transplantation therapy, although the cytotoxicity of CD8 + T cells has been targeted for therapeutic purposes using a calcineurin inhibitor (33) . Thus, our results suggest that the cytotoxicity of NK cells ) and CD8 + T cell-depleted C57BL/6 lymphocytes were co-cultured for 4 h. E/T ratios were 50:1, 25:1, 12.5:1, and 6.25:1. Supernatants were collected and radioactivity measured by a gamma counter. The percentage of specific lysis was calculated according to the following formula: % specific lysis = (experimental-spontaneous) Cr 51 release 9 100/(maximal-spontaneous) Cr 51 release. *P < 0.05, **P < 0.01. BO, bronchiolitis obliterans; EM, elastic-Masson's trichrome; E/T, effector/target ratio; HE, hematoxylin-eosin; mAb, monoclonal antibody; NK, natural killer; Rai-1, retinoic acid early inducible-1.
would also be a good target, and this may lead to the reduced prevalence of BO and better outcome after LTx.
In this study, no difference was found in the expression of TNF-a in isografts or allografts ( Figure 1E ) or in the extent of BO between IFN-ɤ-KO recipients and WT recipients (Figures 2A, B) . TNF-a and IFN-ɤ have been implicated in the pathogenesis of BO (34, 35) , and IFN-ɤ also contributes to allograft acceptance by downregulating T cell proliferation (36) . Therefore, more studies regarding the production of cytokines, such as TNF-a and IFN-ɤ, in the development of BO are needed.
Previously, it has been reported that NKG2D ligands are upregulated during rejection following allogeneic transplantations (37, 38) . Consistent with this, in murine BO the expression of Rae-1, a murine NKG2D ligand, was shown by qPCR and immunohistochemistry to be dramatically upregulated in allografts ( Figures 5A,B) compared with isografts. Similarly, NKG2D and its ligands have been previously shown to be key mediators of NK cell activation during bone marrow transplants (17) . Indeed, in our study, both isografts ( Figures 6A, B) and allografts ( Figures 6A, C) from Rae-1 transgenic mice into WT recipients resulted in the development of BO. Conversely, BO was improved following the injection of anti-NKG2D blocking mAb ( Figures 6D, E) . In addition, allografts ( Figures 6F, G) from Rae-1 transgenic mice into Rag-1 KO recipients, which have NK cells but not T cells or B cells, resulted in the development of BO whereas allografts from WT into Rag-1 KO mice did not. Consistent with previous reports (39, 40) , in vitro analysis revealed that the cytotoxicity of NK cells was markedly affected by the expression of NKG2D ligands in target cells ( Figure 6F ). These results suggest that interaction between NKG2D and its ligands strongly activates the cytotoxicity of NK cells and results in the development of BO in a manner independent of other cell types. Previous research showed that infection, ischemia, and acute lung rejection are all risk factors for BO after LTx (41, 42) , and all of these also lead to the upregulation of NKG2D ligand expression (15) . Therefore, it is possible that upregulation of NKG2D ligands plays a role in the development of BO, and that NKG2D ligands may be useful targets for preventing BO after LTx. On the other hand, there are some differences between the model of heterotopic tracheal transplantation and BO seen in humans following LTx (19) . The pathological lesion in the experimental model involved the large airway and also heterotopic tracheal grafts were not primarily vascularized. Although the model of heterotopic tracheal transplantation recapitulates many morphological features of human BO and shares an essential pathogenesis associated with allo-immune response, these limitations should be noted in understanding our results.
In conclusion, the results of the present study indicate that activation of NK cells through NKG2D and their resulting cytotoxicity play an important role in the development of BO in a heterotopic tracheal transplantation model. This suggests that immunosuppressive therapy targeting NK cells or interaction between NKG2D and its ligands reduce the prevalence of BO after LTx.
